Acute Lymphoblastic Leukemia – Landscape & Forecast – Disease Landscape & Forecast
The acute lymphoblastic leukemia (ALL) therapy market is growing steadily, fueled by innovations in the treatment paradigm. The availability of premium-priced branded agents prescribed in multidrug regimens, particularly Blincyto-based therapies, is impacting the disease’s treatment algorithm. Although multiagent chemotherapy remains the cornerstone of treatment, recently approved therapies (Amgen’s Blincyto and Pfizer’s Besponsa) have expanded the number of options available. CAR T-cell therapies (Novartis’s Kymriah and Kite Pharma’s Tecartus) have also expanded options in the relapse and refractory setting, offering patients additional support. The emerging therapy pipeline continues to grow with therapies such as AbbVie / Roche’s Venclexta / Venclyxto and Bristol Myers Squibb’s CAR T-cell therapy Breyanzi showing promising development. Nevertheless, clinical and commercial potential remains for ALL therapies with improved efficacy, a novel mechanism of action, and/or the ability to treat underserved patient segments, such as T-cell ALL.
Questions answered
- What is the size of the drug-treatable ALL population, and how do the drug-treatment rates vary by geography, line of therapy, and by age?
- How will the use of chemotherapy change over the forecast period, and what impact will the entry of generics have on the ALL market?
- What are thought leaders’ opinions of anti-CD19 CAR T-cell therapies that are approved or in Phase II/III development, such as Kymriah, Tecartus, and Breyanzi?
- What are the drivers of, and constraints on, the ALL market?
- How will the entry of new agents shape this market?
Product description
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Solution enhancement
Disease Landscape & Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.
Disease Landscape & Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.
Table of contents
- Acute Lymphoblastic Leukemia - Landscape & Forecast - Disease Landscape & Forecast
- Key findings
- Acute lymphoblastic leukemia key findings - March 2023
- Key updates
- March 2023
- Market outlook
- Key findings
- Market share of drug classes for ALL: 2021
- Market share of drug classes for ALL: 2031
- Drug-treatable population share and major-market sales share in ALL: 2021
- Drug-treatable population share and major-market sales share in ALL: 2031
- Major-market sales of key agents in ALL: 2021-2031
- Population positioning of current therapies in ALL
- Population positioning of emerging therapies in ALL
- ALL SWOT analysis
- Market drivers and constraints
- What factors are driving the market for ALL?
- What factors are constraining the market for ALL?
- Segment-specific trends
- Patient-share dynamics of key regimens for first-line ALL, Ph- pediatric / AYA (0-24 years) in the United States: 2021-2031
- Patient-share dynamics of key regimens for first-line ALL, Ph+ pediatric / AYA (0-24 years) in the United States: 2021-2031
- Patient-share dynamics of key regimens for second-line ALL, Ph- pediatric / AYA (0-24 years) in the United States: 2021-2031
- Patient-share dynamics of key regimens for third-line ALL, Ph- pediatric / AYA (0-24 years) in the United States: 2021-2031
- Patient-share dynamics of key regimens for second/ third-line ALL, Ph+ pediatric / AYA (0-24 years) in the United States: 2021-2031
- Patient-share dynamics of key regimens for first-line ALL, Ph- adult and older adult (u226525 years) in the United States: 2021-2031
- Patient-share dynamics of key regimens for first-line ALL, Ph+ adult and older adult (u226525 years) in the United States: 2021-2031
- Patient-share dynamics of key regimens for second-line ALL, Ph- adult and older adult (u226525 years) in the United States: 2021-2031
- Patient-share dynamics of key regimens for third-line ALL, Ph- adult and older adult (u226525 years) in the United States: 2021-2031
- Patient-share dynamics of key regimens for second/ third-line ALL, Ph+ adult and older adult (u226525 years) in the United States: 2021-2031
- Key findings
- Forecast
- Market forecast assumptions (pediatric / AYA (0-24 years))
- Market forecast dashboard (pediatric / AYA (0-24 years))
- Market forecast assumptions (adult and older adult (u226525 years))
- Market forecast dashboard (adult and older adult (u226525 years))
- Etiology and pathophysiology
- Disease overview
- Disease pathophysiology
- Overview
- Hematopoiesis: healthy and ALL process
- Select molecular mutations in ALL
- Risk factors
- Select risk factors associated with ALL
- Staging and classification
- WHO classification
- FAB classification
- Risk stratification of ALL
- Key pathways and drug targets
- Select pathways and drug targets
- Disease overview
- Epidemiology
- Key findings
- Epidemiology populations
- Disease definition, methods, and sources used
- Diagnosed incident cases of acute lymphoblastic leukemia: 2021-2031
- Disease definition, methods, and sources used
- Diagnosed incident cases of acute lymphoblastic leukemia by age distribution: 2021-2031
- ALL patient flow
- Drug-treatable cases of pediatric / AYA (0-24 years) ALL: 2021-2031
- Drug-treatable cases of adult and older adult (u2265 25 years) ALL: 2021-2031
- Drug-treated cases of pediatric / AYA (0-24 years) ALL: 2021-2031
- Drug-treated cases of adult and older adult (u2265 25 years) ALL: 2021-2031
- Key findings
- Current treatment
- Key findings
- Treatment goals
- Key endpoints used in clinical trials for ALL
- Key current therapies
- Overview
- Mechanism of action of key current drug classes used for ALL
- Current treatments used for ALL
- Market events impacting the use of key current therapies for ALL
- Key results from select clinical trials investigating imatinib for the treatment of ALL
- Ongoing clinical development of imatinib
- Key ongoing clinical trials of imatinib in the treatment of ALL
- Expert insight: imatinib
- Key results from select clinical trials investigating dasatinib for the treatment of ALL
- Ongoing clinical development of dasatinib
- Key ongoing clinical trials of dasatinib in the treatment of ALL
- Expert insight: dasatinib
- Key results from select clinical trials investigating Iclusig for the treatment of ALL
- Ongoing clinical development of Iclusig
- Expert insight: Iclusig
- Key results from select clinical trials investigating Tasigna for the treatment of ALL
- Key results from select clinical trials investigating Bosulif for the treatment of ALL
- Key results from select clinical trials investigating pegaspargase for the treatment of ALL
- Ongoing clinical development of pegaspargase
- Key ongoing clinical trials of pegaspargase in the treatment of ALL
- Key results from select clinical trials investigating Asparlas for the treatment of ALL
- Ongoing clinical development of Asparlas
- Key ongoing clinical trials of Asparlas in the treatment of ALL
- Key results from select clinical trials investigating recombinant Erwinia asparaginase for the treatment of ALL
- Expert insight: recombinant Erwinia asparaginase
- Key results from select clinical trials investigating vincristine sulfate for the treatment of ALL
- Expert insight: vincristine sulfate
- Key results from select clinical trials investigating clofarabine for the treatment of ALL
- Key results from select clinical trials investigating nelarabine for the treatment of ALL
- Expert insight: nelarabine
- Key results from select clinical trials investigating rituximab for the treatment of ALL
- Expert insight: rituximab
- Key results from select clinical trials investigating Blincyto for the treatment of ALL
- Ongoing clinical development of Blincyto
- Key ongoing clinical trials of Blincyto in the treatment of ALL
- Expert insight: Blincyto
- Key results from select clinical trials investigating Besponsa for the treatment of ALL
- Ongoing clinical development of Besponsa
- Key ongoing clinical trials of Besponsa in the treatment of ALL
- Expert insight: Besponsa
- Key results from select clinical trials investigating Kymriah for the treatment of ALL
- Ongoing clinical development of Kymriah
- Key ongoing clinical trials of Kymriah in the treatment of ALL
- Expert insight: Kymriah
- Tecartus
- Key results from select clinical trials investigating Tecartus for the treatment of ALL
- Ongoing clinical development of Tecartus
- Key ongoing clinical trials of Tecartus in the treatment of ALL
- Expert insight: Tecartus
- Medical practice
- First-line ALL
- Relapsed / refractory ALL
- Patient characteristics influencing drug selection in ALL
- Treatment decision tree for ALL: United States
- Treatment decision tree for ALL: Europe
- Treatment decision tree for ALL: Japan
- Key findings
- Unmet need overview
- Current and future attainment of unmet needs in ALL
- Top unmet needs in ALL: current and future attainment
- Expert insight: unmet need in ALL
- Drug pipeline
- Pipeline
- Regulatory milestones
- Indication comparison
- Emerging therapies
- Key findings
- Key emerging therapies
- Key therapies in development for ALL
- Estimated market authorization dates of key emerging therapies for the treatment of ALL
- Key results of select clinical trials investigating Venclexta / Venclyxto for the treatment of ALL
- Analysis of the clinical development program for Venclexta / Venclyxto
- Key ongoing clinical trials of Venclexta / Venclyxto in the treatment of ALL
- Expert insight: Venclexta / Venclyxto
- Expectations for market authorization and sales opportunity of Venclexta / Venclyxto in ALL
- Analysis of the clinical development program for navitoclax
- Expectations for market authorization and sales opportunity of navitoclax in ALL
- Key results of select clinical trials investigating obecabtagene autoleucel for the treatment of ALL
- Analysis of the clinical development program for obecabtagene autoleucel
- Expert insight: obecabtagene autoleucel
- Expectations for market authorization and sales opportunity of obecabtagene autoleucel in ALL
- Key results of select clinical trials investigating Breyanzi for the treatment of ALL
- Analysis of the clinical development program for Breyanzi
- Key ongoing clinical trials of Breyanzi in the treatment of ALL
- Expert insight: Breyanzi
- Expectations for market authorization and sales opportunity of Breyanzi in ALL
- Analysis of the clinical development program for CTX-110
- Key ongoing clinical trials of CTX-110 in the treatment of ALL
- Expectations for market authorization and sales opportunity of CTX110 in ALL
- Key results of select clinical trials investigating revumenib for the treatment of ALL
- Analysis of the clinical development program for revumenib
- Key ongoing clinical trials of revumenib in the treatment of ALL
- Expert insight: revumenib
- Expectations for market authorization and sales opportunity of revumenib in ALL
- Key results of select clinical trials investigating Darzalex / Darzalex Faspro for the treatment of ALL
- Analysis of the clinical development program for Darzalex / Darzalex Faspro
- Key ongoing clinical trials of Darzalex / Darzalex Faspro in the treatment of ALL
- Expert insight: Darzalex / Darzalex Faspro
- Expectations for market authorization and sales opportunity of Darzalex / Darzalex Faspro in ALL
- Key results of select clinical trials investigating Sarclisa for the treatment of ALL
- Analysis of the clinical development program for Sarclisa
- Expert insight: Sarclisa
- Expectations for market authorization and sales opportunity of Sarclisa in ALL
- Key results of select clinical trials investigating bortezomib for the treatment of ALL
- Analysis of the clinical development program for bortezomib
- Key ongoing clinical trials of bortezomib in the treatment of ALL
- Expectations for market authorization and sales opportunity of bortezomib in ALL
- Early-phase pipeline analysis
- Select compounds in early-phase development for acute lymphoblastic leukemia
- Key findings
- Access & reimbursement overview
- Region-specific reimbursement practices
- Key market access considerations in ALL: United States
- General reimbursement environment: United States
- Key market access considerations in ALL: EU5
- General reimbursement environment: EU5
- Key market access considerations in ALL: Japan
- General reimbursement environment: Japan
- Region-specific reimbursement practices
- Appendix
- Abbreviations
- ALL bibliography
- Key findings
Elliott Puttock, M.Res., Ph.D., is an analyst on the Oncology team at Clarivate. He has experience working in the pharmaceutical sector developing novel therapeutics for ongoing oncology projects. While earning his Ph.D., he specialized in metastatic ovarian cancer and focused on targeting the extracellular matrix to develop new treatments for patients. He obtained his doctorate from Barts Cancer Institute in London.
Yueyao (Alex) Li, M.D., Ph.D., M.S.P.H., is an associate epidemiologist at Clarivate. Previously, she was a postdoctoral researcher at Brown University, where she worked on projects relating to skin cancer and chronic skin conditions. Dr. Li holds a medical degree specializing in general surgery from China Medical University. She also holds a Ph.D. in epidemiology from Indiana University and a master’s degree in public health from the University of South Carolina.